144 related articles for article (PubMed ID: 34651608)
1. Mutational burden and immune recognition of gliomas.
Prost D; Bielle F; Ligon KL; Touat M
Curr Opin Oncol; 2021 Nov; 33(6):626-634. PubMed ID: 34651608
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and therapeutic implications of hypermutation in gliomas.
Touat M; Li YY; Boynton AN; Spurr LF; Iorgulescu JB; Bohrson CL; Cortes-Ciriano I; Birzu C; Geduldig JE; Pelton K; Lim-Fat MJ; Pal S; Ferrer-Luna R; Ramkissoon SH; Dubois F; Bellamy C; Currimjee N; Bonardi J; Qian K; Ho P; Malinowski S; Taquet L; Jones RE; Shetty A; Chow KH; Sharaf R; Pavlick D; Albacker LA; Younan N; Baldini C; Verreault M; Giry M; Guillerm E; Ammari S; Beuvon F; Mokhtari K; Alentorn A; Dehais C; Houillier C; Laigle-Donadey F; Psimaras D; Lee EQ; Nayak L; McFaline-Figueroa JR; Carpentier A; Cornu P; Capelle L; Mathon B; Barnholtz-Sloan JS; Chakravarti A; Bi WL; Chiocca EA; Fehnel KP; Alexandrescu S; Chi SN; Haas-Kogan D; Batchelor TT; Frampton GM; Alexander BM; Huang RY; Ligon AH; Coulet F; Delattre JY; Hoang-Xuan K; Meredith DM; Santagata S; Duval A; Sanson M; Cherniack AD; Wen PY; Reardon DA; Marabelle A; Park PJ; Idbaih A; Beroukhim R; Bandopadhayay P; Bielle F; Ligon KL
Nature; 2020 Apr; 580(7804):517-523. PubMed ID: 32322066
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
Das A; Tabori U; Sambira Nahum LC; Collins NB; Deyell R; Dvir R; Faure-Conter C; Hassall TE; Minturn JE; Edwards M; Brookes E; Bianchi V; Levine A; Stone SC; Sudhaman S; Sanchez Ramirez S; Ercan AB; Stengs L; Chung J; Negm L; Getz G; Maruvka YE; Ertl-Wagner B; Ohashi PS; Pugh T; Hawkins C; Bouffet E; Morgenstern DA
Clin Cancer Res; 2023 Dec; 29(23):4770-4783. PubMed ID: 37126021
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
7. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response.
Weir WH; Mucha PJ; Kim WY
Cell Rep Med; 2022 May; 3(5):100602. PubMed ID: 35584624
[TBL] [Abstract][Full Text] [Related]
8. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
[TBL] [Abstract][Full Text] [Related]
10. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
11. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
[TBL] [Abstract][Full Text] [Related]
13. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
15. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
[TBL] [Abstract][Full Text] [Related]
16. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
17. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
Pan D; Hu AY; Antonia SJ; Li CY
J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.
Westcott PMK; Muyas F; Hauck H; Smith OC; Sacks NJ; Ely ZA; Jaeger AM; Rideout WM; Zhang D; Bhutkar A; Beytagh MC; Canner DA; Jaramillo GC; Bronson RT; Naranjo S; Jin A; Patten JJ; Cruz AM; Shanahan SL; Cortes-Ciriano I; Jacks T
Nat Genet; 2023 Oct; 55(10):1686-1695. PubMed ID: 37709863
[TBL] [Abstract][Full Text] [Related]
19. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
[TBL] [Abstract][Full Text] [Related]
20. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
